{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "binds",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00713",
      "entity_text" : "HLA class I molecules",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P15056",
      "entity_text" : "BRAF",
      "features" : [ {
        "to_base" : "V",
        "site" : 600,
        "feature_type" : "mutation",
        "evidence" : "V600E"
      } ],
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Having established that the BRAF V600E derived neopeptide KIGDFGLATEK can bind to two HLA class I molecules that are relatively frequent in the Caucasian population, we evaluated whether BRAF V600E mutated LCH-patients expressing HLA-A * 03:01 and/or HLA-A * 11:01 had increased event-free survival as compared to LCH-patients without these HLA genotypes.",
  "reading_complete" : "2020-08-04T10:52:14Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T10:47:08Z",
  "trigger" : "bind",
  "evidence" : [ "BRAF V600E  derived neopeptide KIGDFGLATEK can bind to two HLA class I molecules" ],
  "pmc_id" : "6967030",
  "score" : 0
}